

LONDON NOTICE NO. 3634

Issue Date:

12 September 2012

Effective Date:

12 September 2012

UNIVERSAL STOCK FUTURES CONTRACT (BASED ON COMPANY SHARES AND DEPOSITARY RECEIPTS) (EXCHANGE CONTRACT NO. 66F)

OPTION CONTRACT ON EQUITY RELATED SECURITIES (INCLUDING COMPANY SHARES, DEPOSITARY RECEIPTS AND EXCHANGE TRADED FUND SHARES) (EXCHANGE CONTRACT NO. 201F)

EQUITY RELATED SECURITY CONTRACT (INCLUDING COMPANY SHARES, DEPOSITARY RECEIPTS AND EXCHANGE TRADED FUND SHARES) (EXCHANGE CONTRACT NO. 211)

DELISTING WITHIN BCLEAR OF CONTRACTS ON Q-CELLS AG SHARES

Executive Summary

This Notice informs Members that, with effect from the close of business on 12 September 2012, flexible Universal Stock Futures Contracts and flexible Individual Equity Option Contracts based on the company shares of Q-Cells AG have been delisted from Bclear.

1. This Notice informs Members that, with effect from the close of business on 12 September 2012 the following contracts have been delisted from Bclear:

- (a) flexible Universal Stock Futures Contracts; and

Company Name	USF Contract Codes	
	Cash Settled Flexible USF	Physically Delivered Flexible USF
Q-Cells AG	QDD	QDH

- (b) flexible Individual Equity Option Contracts.

Company Name	Option Contract Codes			
	American Style Cash Settled Flexible	American Style Physically Delivered Flexible	European Style Cash Settled Flexible	European style Physically delivered Flexible
Q-Cells AG	QDW	QDO	QDB	QDV

The **Euronext Derivatives Markets** comprise the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets. Euronext is part of the NYSE Euronext group.

2. Updated Lists of Contract Details in respect of Exchange Contracts No. 66F, No 201F and No. 211 will be made available in the London Market Handbook on the NYSE Euronext website (www.nyx.com/londonmarkethandbook) in due course.

For further information in relation to this Notice, Members should contact:

Equity Derivatives Product Management +44 (0) 20 7379 2200

equities@nyx.com